LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Начало・Списък с акции・Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc

Затворен

СекторЗдравеопазване

23.38 1.56

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

22.98

Максимум

23.39

Ключови измерители
By Trading Economics
Приходи	51M -129M
Продажби	207M
Марж на печалбата	-62.319
Служители	1,371
EBITDA	8.8M -105M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+128.09% upside

Дивиденти
By Dow Jones
Следващи печалби	5.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	192M 2.2B
Предишно отваряне	21.82
Предишно затваряне	23.38

Настроения в новините

By Acuity

50%

154 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

32.76 / 39.24 Подкрепа & съпротива

Ultragenyx Pharmaceutical Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.03.2026 г., 23:35 ч. UTC

Значими събития в новините

Oil Prices Jump in Asia as U.S.-Iran Conflict Stokes Supply Fears -- Energy Comment

1.03.2026 г., 23:49 ч. UTC

Пазарно говорене

Значими събития в новините

Australian Gold-Mining Stocks Rally as Attack on Iran Drives Gold Higher -- Market Talk

1.03.2026 г., 23:47 ч. UTC

Пазарно говорене

Значими събития в новините

Gold, Silver Rise as Middle East Conflict Spurs Safe-Haven Demand -- Market Talk

1.03.2026 г., 23:41 ч. UTC

Пазарно говорене

Значими събития в новините

Lasting Oil Price Shock Could Stoke Global Inflation -- Market Talk

1.03.2026 г., 23:39 ч. UTC

Пазарно говорене

Значими събития в новините

Global Equities Roundup: Market Talk

1.03.2026 г., 23:39 ч. UTC

Пазарно говорене

Значими събития в новините

Nikkei May Fall Amid Concerns About Higher Energy Prices -- Market Talk

1.03.2026 г., 23:36 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Jumps as Middle East Conflict Heightens Supply Disruption Concerns -- Market Talk

1.03.2026 г., 23:24 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

1.03.2026 г., 23:24 ч. UTC

Пазарно говорене

Financial Markets Trim Bets on RBA Hike in May -- Market Talk

1.03.2026 г., 23:21 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

1.03.2026 г., 23:21 ч. UTC

Пазарно говорене

Sky Network TV's Risk/Reward Still Not Attractive -- Market Talk

1.03.2026 г., 23:19 ч. UTC

Значими събития в новините

Front-Month Brent Crude Oil Futures Rose 8.5% to $79.08/bbl

1.03.2026 г., 23:17 ч. UTC

Значими събития в новините

Front-Month WTI Crude Oil Futures Rose 8.4% to $72.65/bbl

1.03.2026 г., 23:14 ч. UTC

Значими събития в новините

Front-Month WTI Crude Oil Futures Extend Gains in Early Trade

1.03.2026 г., 22:55 ч. UTC

Значими събития в новините

Spot Gold Rises 1.9% to $5,278.61/oz Amid Middle East Conflict

1.03.2026 г., 22:54 ч. UTC

Значими събития в новините

Front-Month WTI Crude Oil Futures Rise Amid Middle East Conflict

1.03.2026 г., 22:53 ч. UTC

Значими събития в новините

Front-Month WTI Crude Oil Futures Rise 3.2% to $67.29/bbl

1.03.2026 г., 22:38 ч. UTC

Пазарно говорене

Значими събития в новините

Attack on Iran Likely to Push Up Floor Under Gold -- Market Talk

1.03.2026 г., 22:21 ч. UTC

Печалби

Berkshire's Earnings Weren't as Bad as They Looked. A Goodwill Write-Down Hit Operating Profits. -- Barrons.com

1.03.2026 г., 22:17 ч. UTC

Пазарно говорене

Financial Markets Trim Bets On RBA Hike In May -- Market Talk

1.03.2026 г., 22:13 ч. UTC

Пазарно говорене

Значими събития в новините

OPEC+ Oil Output Boost Could Be Moot if Strait of Hormuz Unavailable -- Market Talk

1.03.2026 г., 22:00 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Could Surge Above $100 If Flows Don't Return to Normal Quickly -- Market Talk

1.03.2026 г., 21:40 ч. UTC

Пазарно говорене

Значими събития в новините

Spot Gold Up as Investors Shield Against Risk -- Market Talk

1.03.2026 г., 21:35 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Prices Seen Rising to Low to Mid-US$80s Per Barrel -- Market Talk

1.03.2026 г., 21:30 ч. UTC

Пазарно говорене

Australian Dollar Weakens Most as Trader Fear Long-Term Conflict -- Market Talk

1.03.2026 г., 21:27 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Prices Likely to Rise on Iran Conflict But to Manageable Levels -- Market Talk

1.03.2026 г., 21:19 ч. UTC

Пазарно говорене

Значими събития в новините

Shipping Disruptions 'More Acute Risk' Than Oil Output From Iran Conflict -- Market Talk

1.03.2026 г., 20:58 ч. UTC

Пазарно говорене

Значими събития в новините

Risk Off Stance in Markets Amid Fears of Wider Conflict -- Market Talk

1.03.2026 г., 20:40 ч. UTC

Пазарно говорене

Australia Dollar to Fall Sharply Against U.S. Dollar on Middle East Conflict -- Market Talk

1.03.2026 г., 20:24 ч. UTC

Пазарно говорене

Значими събития в новините

Brent Crude at $100/bbl Could Slow Pace of Global Rate Cuts -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Ultragenyx Pharmaceutical Inc Прогноза

Ценова цел

By TipRanks

128.09% нагоре

12-месечна прогноза

Среден 53.35 USD 128.09%

Висок 84 USD

Нисък 25 USD

Според 21 анализатори от Wall Street, предложили 12-месечна ценова цел за Ultragenyx Pharmaceutical Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

21 ratings

Купи

Задържане

Продай

Според 21 анализатори, дали борсови рейтинги на Ultragenyx Pharmaceutical Inc през последните 3 месеца.

Техническа оценка

By Trading Central

32.76 / 39.24Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Настроение

By Acuity

154 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.